Research programme: anti-emesis therapeutics - Myriad Pharmaceuticals

Drug Profile

Research programme: anti-emesis therapeutics - Myriad Pharmaceuticals

Alternative Names: MPC-4505

Latest Information Update: 13 Aug 2007

Price : $50

At a glance

  • Originator Myriad Genetics
  • Class
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 13 Aug 2007 Discontinued - Preclinical for Nausea and vomiting in USA (unspecified route)
  • 15 Jan 2007 Preclinical development is ongoing
  • 21 Apr 2004 Preclinical trials in Emesis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top